Document Detail

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
MedLine Citation:
PMID:  19123199     Owner:  NLM     Status:  In-Process    
OBJECTIVE: The main objective of this study was to investigate possible predictors of response to cholinesterase inhibitor (ChEI) treatment, including pre-treatment progression rates and levels of the cerebrospinal fluid (CSF) biomarkers. A secondary objective was to evaluate whether treatment with ChEI changed progression. METHODS: Out-patient individuals (n = 191) with the clinical diagnosis of Alzheimer's disease received ChEI treatment and were part of the Swedish Alzheimer Treatment Study (SATS), a prospective, longitudinal, non-randomised study in a routine clinical setting. Patients were assessed with MMSE, ADAS-cog and a global rating (CIBIC) at baseline, 2 months and every 6 months for a total period of 3 years. The following potential predictors of treatment response were investigated: age, gender, APOE epsilon 4 carrier, education, duration of disease, cognitive level, pre-treatment progression rate (in MMSE) and the levels of the CSF biomarkers A beta 42, T-tau and P-tau. RESULTS: Fast pre-treatment progression rate was a predictor of treatment response even after adjusting for baseline severity, another positive predictor of response. Patients in the fastest quartile of pre-treatment progression rates were significantly more prone to be responders at 2 months (adjusted OR 6.6, p = 0.001) and 6 months (adjusted OR 10.4, p < 0.001) than those in the slowest progressing quartile. Moreover, the linearity of progression was significantly changed by ChEI treatment at 6 months compared to the pre-treatment period. CONCLUSION: The rate of pre-treatment progression was the most consistent positive predictor of ChEI treatment response in the routine clinical setting. The progression rate was significantly changed by ChEI treatment.
A K Wallin; O Hansson; K Blennow; E Londos; L Minthon
Related Documents :
20589639 - Juvenile xanthogranuloma with hematological dysfunction treated with 2cda-arac.
18217509 - Risk of meningitis with cerebrospinal fluid rhinorrhea.
3493819 - Photopheresis--extracorporeal irradiation of 8-mop containing blood--a new therapeutic ...
1355219 - Efficacy and toxicity of eflornithine for treatment of trypanosoma brucei gambiense sle...
25112879 - A revision of metaleptobasis calvert (odonata: coenagrionidae) with seven synonymies a...
19605849 - First-line therapy with fludarabine compared with chlorambucil does not result in a maj...
22034019 - Low-concentration infracyanine green-assisted internal limiting membrane peeling in idi...
15692919 - Clinical outcome for on-pump myocardial revascularization in patients with mild renal d...
2971049 - Transcatheter embolotherapy of massive bleeding after surgery for benign gynecologic di...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of geriatric psychiatry     Volume:  24     ISSN:  1099-1166     ISO Abbreviation:  Int J Geriatr Psychiatry     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710629     Medline TA:  Int J Geriatr Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  638-47     Citation Subset:  IM    
Copyright Information:
(c) 2009 John Wiley & Sons, Ltd.
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolation of phospholipase D mutants having phosphatidylinositol-synthesizing activity with position...
Next Document:  Models for chromosomal replication-independent non-B DNA structure-induced genetic instability.